US FDA Moves Homeopathic Drug Enforcement To Risk-Based Approach
Products with routes of administration other than oral and topical or intended to be used for the prevention or treatment of serious or life-threatening diseases and conditions will be among those prioritized for enforcement and "regulatory actions," draft guidance notes.
You may also be interested in...
Rep. McNerneny's amendment calls for process that would follow steps FDA used in exercising enforcement discretion on natural products that contain levels of an approved drug ingredient, with red yeast rice most notable. But critics of FDA's VMS industry oversight don't see McNerney's amendment as effective not only for strengthening FDA's overall regulation but also for solving its CBD problem.
Nutra Pharma’s Nyloxin claims to relieve cancer pain and potentially help treat opioid addiction, among others, mark its products as unapproved new drugs, FDA asserts in a warning letter that reflects its homeopathic enforcement approach proposed in late 2017. “Health fraud scams like these are inexcusable,” says FDA Commissioner Scott Gottlieb.
American Association of Homeopathic Pharmacists says Borneman "contributed to monumental changes in the development of homeopathic drugs and their regulation" and "represented and defended homeopathy against uninformed regulation and vanity medical products masquerading as homeopathic."